Nanoparticle Delivery System Shows Promise for Enhancing Immune Cell Treatment of Ovarian Cancer
Researchers conjugated the PD-L1 inhibitor BMS202 to nanodiamonds and found the combination significantly enhanced γδ T cell-mediated killing of metastatic ovarian cancer cells in vitro. The study used patient-derived ascites cells treated with activated platelets to mimic the immunosuppressive, platelet-cloaked tumor microenvironment seen in metastatic ovarian cancer. The findings suggest nanodiamond-based drug delivery could help overcome a key resistance mechanism to immune checkpoint therapy in ovarian cancer.
A preprint study posted to bioRxiv reports that delivering the PD-L1 inhibitor BMS202 via nanodiamonds (NDs) substantially improved the ability of γδ T cells to kill metastatic ovarian cancer cells in laboratory conditions. Ovarian cancer has shown limited response to immune checkpoint inhibitors, in part because platelets physically cloak tumor cells and create an immunosuppressive tumor microenvironment. To model this, researchers exposed patient-derived ascites cells to activated platelets before applying ND/BMS202 nanocomplexes and co-culturing them with expanded γδ T cells. The nanodiamond-delivered BMS202 outperformed free BMS202, with increased markers of immune activation including CD107a degranulation, Granzyme B release, caspase cleavage, and γ-H2AX DNA damage signaling. The authors acknowledge a key limitation: direct evidence of PD-L1 target engagement or PD-1/PD-L1 binding inhibition was not demonstrated, leaving the precise mechanism partially unconfirmed. They call for further validation in patient-derived organoid models before the approach can be considered for clinical translation.
What's missing
The study is a preprint and has not yet undergone peer review. It is entirely in vitro, with no animal or human data; it is unknown whether nanodiamonds would safely and effectively deliver BMS202 in a living organism. The study also does not address the pharmacokinetics, toxicity profile, or scalability of ND/BMS202 nanocomplexes.
What different sources said
- bioRxivCenter
Nanoparticle mediated delivery of PD-L1 inhibitor enhances γδ T cell immunotherapy against metastatic ovarian cancer cells
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.